Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research note released on Friday,Benzinga reports.

Several other research firms also recently issued reports on SPRO. TD Cowen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. HC Wainwright cut their price target on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, November 4th.

Spero Therapeutics Trading Down 5.6 %

SPRO opened at $1.18 on Friday. Spero Therapeutics has a 1-year low of $1.01 and a 1-year high of $1.89. The firm has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.36. The stock has a market capitalization of $63.71 million, a PE ratio of 16.86 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

Several large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of Spero Therapeutics during the 1st quarter valued at $31,000. Renaissance Technologies LLC increased its holdings in Spero Therapeutics by 14.2% in the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after purchasing an additional 121,492 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Spero Therapeutics by 121.8% in the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after buying an additional 418,742 shares during the period. Murchinson Ltd. boosted its holdings in Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares during the period. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.